Last reviewed · How we verify

Novosis(bongros/BMP-2)

Daewoong Pharmaceutical Co. LTD. · Phase 3 active Small molecule

Novosis(bongros/BMP-2) is a Recombinant protein growth factor Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development for Bone regeneration and fracture healing in orthopedic surgery, Spinal fusion procedures.

Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.

Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth. Used for Bone regeneration and fracture healing in orthopedic surgery, Spinal fusion procedures.

At a glance

Generic nameNovosis(bongros/BMP-2)
SponsorDaewoong Pharmaceutical Co. LTD.
Drug classRecombinant protein growth factor
TargetBMP-2 receptor (ALK2/ALK3)
ModalitySmall molecule
Therapeutic areaOrthopedics / Bone regeneration
PhasePhase 3

Mechanism of action

BMP-2 is a growth factor that belongs to the transforming growth factor-beta (TGF-β) superfamily and acts as a potent osteoinductive agent. It binds to serine/threonine kinase receptors on osteoprogenitor cells, triggering intracellular signaling cascades that promote differentiation into mature osteoblasts and subsequent bone matrix deposition. This mechanism makes it effective for enhancing bone regeneration in surgical and trauma settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Novosis(bongros/BMP-2)

What is Novosis(bongros/BMP-2)?

Novosis(bongros/BMP-2) is a Recombinant protein growth factor drug developed by Daewoong Pharmaceutical Co. LTD., indicated for Bone regeneration and fracture healing in orthopedic surgery, Spinal fusion procedures.

How does Novosis(bongros/BMP-2) work?

Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.

What is Novosis(bongros/BMP-2) used for?

Novosis(bongros/BMP-2) is indicated for Bone regeneration and fracture healing in orthopedic surgery, Spinal fusion procedures.

Who makes Novosis(bongros/BMP-2)?

Novosis(bongros/BMP-2) is developed by Daewoong Pharmaceutical Co. LTD. (see full Daewoong Pharmaceutical Co. LTD. pipeline at /company/daewoong-pharmaceutical-co-ltd).

What drug class is Novosis(bongros/BMP-2) in?

Novosis(bongros/BMP-2) belongs to the Recombinant protein growth factor class. See all Recombinant protein growth factor drugs at /class/recombinant-protein-growth-factor.

What development phase is Novosis(bongros/BMP-2) in?

Novosis(bongros/BMP-2) is in Phase 3.

What are the side effects of Novosis(bongros/BMP-2)?

Common side effects of Novosis(bongros/BMP-2) include Swelling and inflammation at application site, Osteoclast activation and bone resorption, Ectopic bone formation.

What does Novosis(bongros/BMP-2) target?

Novosis(bongros/BMP-2) targets BMP-2 receptor (ALK2/ALK3) and is a Recombinant protein growth factor.

Related